Effects of Toll-like receptor stimulation on eosinophilic infiltration in lungs of BALB/c mice immunized with UV-inactivated severe acute respiratory syndrome-related coronavirus vaccine

Journal of Virology

Volumn 88, Issue 15, 2014, Pages 8597-8614

  Iwata Yoshikawa, Naoko ^a   Uda, Akihiko ^a   Suzuki, Tadaki ^a   Tsunetsugu Yokota, Yasuko ^a,b   Sato, Yuko ^a   Morikawa, Shigeru ^a   Tashiro, Masato ^a   Sata, Tetsutaro ^a   Hasegawa, Hideki ^a   Nagata, Noriyo ^a  

^a NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^b TOKYO UNIVERSITY OF TECHNOLOGY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

EOTAXIN; INTERLEUKIN 13; INTERLEUKIN 4; LIPOPOLYSACCHARIDE; NUCLEOCAPSID PROTEIN; SEVERE ACUTE RESPIRATORY SYNDROME VACCINE; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR AGONIST;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD11B+ CELL; CELL MOTION; CHEMOTAXIS; CONTROLLED STUDY; ENZYME ACTIVATION; EOSINOPHIL; EOSINOPHILIA; FEMALE; GENE INDUCTION; HELPER CELL; IMMUNIZATION; IMMUNOPATHOLOGY; LD 50; LEUKOCYTE MIGRATION; LUNG INFILTRATE; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; POLARIZATION; PRIORITY JOURNAL; SARS CORONAVIRUS; SEVERE ACUTE RESPIRATORY SYNDROME; TH2 CELL; ULTRAVIOLET RADIATION; UPREGULATION; VIRUS ISOLATION;

ANIMALS; CHEMOKINES; EOSINOPHILS; GENE EXPRESSION PROFILING; INTERLEUKIN-13; INTERLEUKIN-4; LUNG; MICE; MICE, INBRED BALB C; MICROARRAY ANALYSIS; RECEPTORS, VIRUS; SARS VIRUS; SEVERE ACUTE RESPIRATORY SYNDROME; SURVIVAL ANALYSIS; TOLL-LIKE RECEPTORS; VACCINES, INACTIVATED; VIRAL VACCINES;

EID: 84903900023     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00983-14     Document Type: Article

References (56)

1. Drosten C, Gunther S, Preiser W, van der Werf S, Brodt HR, Becker S, Rabenau H, Panning M, Kolesnikova L, Fouchier RA, Berger A, Burguiere AM, Cinatl J, Eickmann M, Escriou N, Grywna K, Kramme S, Manuguerra JC, Muller S, Rickerts V, Sturmer M, Vieth S, Klenk HD, Osterhaus AD, Schmitz H, Doerr HW. 2003. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N. Engl. J. Med. 348:1967-1976. http://dx.doi.org/10.1056/NEJMoa030747.
2. Ksiazek TG, Erdman D, Goldsmith CS, Zaki SR, Peret T, Emery S, Tong S, Urbani C, Comer JA, Lim W, Rollin PE, Dowell SF, Ling AE, Humphrey CD, Shieh WJ, Guarner J, Paddock CD, Rota P, Fields B, DeRisi J, Yang JY, Cox N, Hughes JM, LeDuc JW, Bellini WJ, Anderson LJ. 2003. A novel coronavirus associated with severe acute respiratory syndrome. N. Engl. J. Med. 348:1953-1966. http://dx.doi.org/10.1056/NEJMoa030781.
3. Peiris JSM, Lai ST, Poon LLM, Guan Y, Yam LYC, Lim W, Nicholls J, Yee WKS, Yan WW, Cheung MT, Cheng VCC, Chan KH, Tsang DNC, Yung RWH, Ng TK, Yuen KY. 2003. Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet 361:1319-1325. http://dx.doi.org/10.1016/S0140-6736(03)13077-2.
4. Rota PA, Oberste MS, Monroe SS, Nix WA, Campagnoli R, Icenogle JP, Penaranda S, Bankamp B, Maher K, Chen MH, Tong S, Tamin A, Lowe L, Frace M, DeRisi JL, Chen Q, Wang D, Erdman DD, Peret TC, Burns C, Ksiazek TG, Rollin PE, Sanchez A, Liffick S, Holloway B, Limor J, McCaustland K, Olsen-Rasmussen M, Fouchier R, Gunther S, Osterhaus AD, Drosten C, Pallansch MA, Anderson LJ, Bellini WJ. 2003. Characterization of a novel coronavirus associated with severe acute respiratory syndrome. Science 300:1394-1399. http://dx.doi.org/10.1126/science.1085952.
5. He Y, Zhou Y, Siddiqui P, Jiang S. 2004. Inactivated SARS-CoV vaccine elicits high titers of spike protein-specific antibodies that block receptor binding and virus entry. Biochem. Biophys. Res. Commun. 325:445-452. http://dx.doi.org/10.1016/j.bbrc.2004.10.052.
6. Takasuka N, Fujii H, Takahashi Y, Kasai M, Morikawa S, Itamura S, Ishii K, Sakaguchi M, Ohnishi K, Ohshima M, Hashimoto S, Odagiri T, Tashiro M, Yoshikura H, Takemori T, Tsunetsugu-Yokota Y. 2004. A subcutaneously injected UV-inactivated SARS coronavirus vaccine elicits systemic humoral immunity in mice. Int. Immunol. 16:1423-1430. http://dx.doi.org/10.1093/intimm/dxh143.
7. Tang L, Zhu Q, Qin E, Yu M, Ding Z, Shi H, Cheng X, Wang C, Chang G, Zhu Q, Fang F, Chang H, Li S, Zhang X, Chen X, Yu J, Wang J, Chen Z. 2004. Inactivated SARS-CoV vaccine prepared from whole virus induces a high level of neutralizing antibodies in BALB/c mice. DNA Cell Biol. 23:391-394. http://dx.doi.org/10.1089/104454904323145272.
8. Xiong S, Wang YF, Zhang MY, Liu XJ, Zhang CH, Liu SS, Qian CW, Li JX, Lu JH, Wan ZY, Zheng HY, Yan XG, Meng MJ, Fan JL. 2004. Immunogenicity of SARS inactivated vaccine in BALB/c mice. Immunol. Lett. 95:139-143. http://dx.doi.org/10.1016/j.imlet.2004.06.014.
9. Qu D, Zheng B, Yao X, Guan Y, Yuan ZH, Zhong NS, Lu LW, Xie JP, Wen YM. 2005. Intranasal immunization with inactivated SARS-CoV (SARSassociated coronavirus) induced local and serum antibodies in mice. Vaccine 23:924-931. http://dx.doi.org/10.1016/j.vaccine.2004.07.031.
10. Zhang CH, Lu JH, Wang YF, Zheng HY, Xiong S, Zhang MY, Liu XJ, Li JX, Wan ZY, Yan XG, Qi SY, Cui Z, Zhang B. 2005. Immune responses in Balb/c mice induced by a candidate SARS-CoV inactivated vaccine prepared from F69 strain. Vaccine 23:3196-3201. http://dx.doi.org/10.1016/j.vaccine.2004.11.073.
11. Deming D, Sheahan T, Heise M, Yount B, Davis N, Sims A, Suthar M, Harkema J, Whitmore A, Pickles R, West A, Donaldson E, Curtis K, Johnston R, Baric R. 2006. Vaccine efficacy in senescent mice challenged with recombinant SARS-CoV bearing epidemic and zoonotic spike variants. PLoS Med. 3:e525. http://dx.doi.org/10.1371/journal.pmed.0030525.
12. Yasui F, Kai C, Kitabatake M, Inoue S, Yoneda M, Yokochi S, Kase R, Sekiguchi S, Morita K, Hishima T, Suzuki H, Karamatsu K, Yasutomi Y, Shida H, Kidokoro M, Mizuno K, Matsushima K, Kohara M. 2008. Prior immunization with severe acute respiratory syndrome (SARS)-associated coronavirus (SARS-CoV) nucleocapsid protein causes severe pneumonia in mice infected with SARS-CoV. J. Immunol. 181:6337-6348. http://dx.doi.org/10.4049/jimmunol.181.9.6337.
13. Bolles M, Deming D, Long K, Agnihothram S, Whitmore A, Ferris M, Funkhouser W, Gralinski L, Totura A, Heise M, Baric RS. 2011. A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge. J. Virol. 85:12201-12215. http://dx.doi.org/10.1128/JVI.06048-11.
14. Tseng CT, Sbrana E, Iwata-Yoshikawa N, Newman PC, Garron T, Atmar RL, Peters CJ, Couch RB. 2012. Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus. PLoS One 7:e35421. http://dx.doi.org/10.1371/journal.pone.0035421.
15. Neuman BW, Adair BD, Yoshioka C, Quispe JD, Orca G, Kuhn P, Milligan RA, Yeager M, Buchmeier MJ. 2006. Supramolecular architecture of severe acute respiratory syndrome coronavirus revealed by electron cryomicroscopy. J. Virol. 80:7918-7928. http://dx.doi.org/10.1128/JVI.00645-06.
16. Kim HW, Canchola JG, Brandt CD, Pyles G, Chanock RM, Jensen K, Parrott RH. 1969. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am. J. Epidemiol. 89:422-434.
17. Olson MR, Varga SM. 2008. Pulmonary immunity and immunopathology: lessons from respiratory syncytial virus. Expert Rev. Vaccines 7:1239-1255. http://dx.doi.org/10.1586/14760584.7.8.1239.
18. Delgado MF, Coviello S, Monsalvo AC, Melendi GA, Hernandez JZ, Batalle JP, Diaz L, Trento A, Chang HY, Mitzner W, Ravetch J, Melero JA, Irusta PM, Polack FP. 2009. Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease. Nat. Med. 15:34-41. http://dx.doi.org/10.1038/nm.1894.
19. Nagata N, Iwata N, Hasegawa H, Fukushi S, Harashima A, Sato Y, Saijo M, Taguchi F, Morikawa S, Sata T. 2008. Mouse-passaged severe acute respiratory syndrome-associated coronavirus leads to lethal pulmonary edema and diffuse alveolar damage in adult but not young mice. Am. J. Pathol. 172:1625-1637. http://dx.doi.org/10.2353/ajpath.2008.071060.
20. Nagata N, Iwata N, Hasegawa H, Sato Y, Morikawa S, Saijo M, Itamura S, Saito T, Ami Y, Odagiri T, Tashiro M, Sata T. 2007. Pathology and virus dispersion in cynomolgus monkeys experimentally infected with severe acute respiratory syndrome coronavirus via different inoculation routes. Int. J. Exp. Pathol. 88:403-414. http://dx.doi.org/10.1111/j.1365-2613.2007.00567.x.
21. Zhang X, Goncalves R, Mosser DM. 2008. The isolation and characterization of murine macrophages. Curr. Protoc. Immunol. 83:14.1-14.1.14. http://dx.doi.org/10.1002/0471142735.im1401s83.
22. Sugiura N, Uda A, Inoue S, Kojima D, Hamamoto N, Kaku Y, Okutani A, Noguchi A, Park CH, Yamada A. 2011. Gene expression analysis of host innate immune responses in the central nervous system following lethal CVS-11 infection in mice. Jpn. J. Infect. Dis. 64:463-472.
23. Kaisho T, Akira S. 2002. Toll-like receptors as adjuvant receptors. Biochim. Biophys. Acta 1589:1-13. http://dx.doi.org/10.1016/S0167-4889 (01)00182-3.
24. Pashine A, Valiante NM, Ulmer JB. 2005. Targeting the innate immune response with improved vaccine adjuvants. Nat. Med. 11:S63-S68. http://dx.doi.org/10.1038/nm1210.
25. O'Neill LA, Bowie AG. 2007. The family of five: TIR-domain-containing adaptors in Toll-like receptor signalling. Nat. Rev. Immunol. 7:353-364. http://dx.doi.org/10.1038/nri2079.
26. O'Mahony DS, Pham U, Iyer R, Hawn TR, Liles WC. 2008. Differential constitutive and cytokine-modulated expression of human Toll-like receptors in primary neutrophils, monocytes, and macrophages. Int. J. Med. Sci. 5:1-8. http://dx.doi.org/10.7150/ijms.5.1.
27. Applequist SE, Wallin RP, Ljunggren HG. 2002. Variable expression of Toll-like receptor in murine innate and adaptive immune cell lines. Int. Immunol. 14:1065-1074. http://dx.doi.org/10.1093/intimm/dxf069.
28. Roper RL, Rehm KE. 2009. SARS vaccines: where are we? Expert Rev. Vaccines 8:887-898. http://dx.doi.org/10.1586/erv.09.43.
29. Buchholz UJ, Bukreyev A, Yang L, Lamirande EW, Murphy BR, Subbarao K, Collins PL. 2004. Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity. Proc. Natl. Acad. Sci. U.S.A. 101:9804-9809. http://dx.doi.org/10.1073/pnas.0403492101.
30. Bukreyev A, Lamirande EW, Buchholz UJ, Vogel LN, Elkins WR, St Claire M, Murphy BR, Subbarao K, Collins PL. 2004. Mucosal immunisation of African green monkeys (Cercopithecus aethiops) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARS. Lancet 363:2122-2127. http://dx.doi.org/10.1016/S0140-6736(04)16501-X.
31. Ishii K, Hasegawa H, Nagata N, Mizutani T, Morikawa S, Suzuki T, Taguchi F, Tashiro M, Takemori T, Miyamura T, Tsunetsugu-Yokota Y. 2006. Induction of protective immunity against severe acute respiratory syndrome coronavirus (SARS-CoV) infection using highly attenuated recombinant vaccinia virus DIs. Virology 351:368-380. http://dx.doi.org/10.1016/j.virol.2006.03.020.
32. Guo JP, Petric M, Campbell W, McGeer PL. 2004. SARS corona virus peptides recognized by antibodies in the sera of convalescent cases. Virology 324:251-256. http://dx.doi.org/10.1016/j.virol.2004.04.017.
33. Hanley KA. 2011. The double-edged sword: how evolution can make or break a live-attenuated virus vaccine. Evolution 4:635-643. http://dx.doi.org/10.1007/s12052-011-0365-y.
34. DeDiego ML, Alvarez E, Almazan F, Rejas MT, Lamirande E, Roberts A, Shieh WJ, Zaki SR, Subbarao K, Enjuanes L. 2007. A severe acute respiratory syndrome coronavirus that lacks the E gene is attenuated in vitro and in vivo. J. Virol. 81:1701-1713. http://dx.doi.org/10.1128/JVI.01467-06.
35. Dediego ML, Pewe L, Alvarez E, Rejas MT, Perlman S, Enjuanes L. 2008. Pathogenicity of severe acute respiratory coronavirus deletion mutants in hACE-2 transgenic mice. Virology 376:379-389. http://dx.doi.org/10.1016/j.virol.2008.03.005.
36. Lamirande EW, DeDiego ML, Roberts A, Jackson JP, Alvarez E, Sheahan T, Shieh WJ, Zaki SR, Baric R, Enjuanes L, Subbarao K. 2008. A live attenuated severe acute respiratory syndrome coronavirus is immunogenic and efficacious in golden Syrian hamsters. J. Virol. 82:7721-7724. http://dx.doi.org/10.1128/JVI.00304-08.
37. Tsunetsugu-Yokota Y. 2008. Large-scale preparation of UV-inactivated SARS coronavirus virions for vaccine antigen. Methods Mol. Biol. 454: 119-126. http://dx.doi.org/10.1007/978-1-59745-181-9_11.
38. Hancock GE, Speelman DJ, Heers K, Bortell E, Smith J, Cosco C. 1996. Generation of atypical pulmonary inflammatory responses in BALB/c mice after immunization with the native attachment (G) glycoprotein of respiratory syncytial virus. J. Virol. 70:7783-7791.
39. De Swart RL, Kuiken T, Timmerman HH, van Amerongen G, Van Den Hoogen BG, Vos HW, Neijens HJ, Andeweg AC, Osterhaus AD. 2002. Immunization of macaques with formalin-inactivated respiratory syncytial virus (RSV) induces interleukin-13-associated hypersensitivity to subsequent RSV infection. J. Virol. 76:11561-11569. http://dx.doi.org/10.1128/JVI.76.22.11561-11569.2002.
40. Johnson TR, Varga SM, Braciale TJ, Graham BS. 2004. Vbeta14(+) T cells mediate the vaccine-enhanced disease induced by immunization with respiratory syncytial virus (RSV) G glycoprotein but not with formalin-inactivated RSV. J. Virol. 78:8753-8760. http://dx.doi.org/10.1128/JVI.78.16.8753-8760.2004.
41. Johnson TR, Graham BS. 1999. Secreted respiratory syncytial virus G glycoprotein induces interleukin-5 (IL-5), IL-13, and eosinophilia by an IL-4-independent mechanism. J. Virol. 73:8485-8495.
42. Johnson TR, Parker RA, Johnson JE, Graham BS. 2003. IL-13 is sufficient for respiratory syncytial virus G glycoprotein-induced eosinophilia after respiratory syncytial virus challenge. J. Immunol. 170:2037-2045. http://dx.doi.org/10.4049/jimmunol.170.4.2037.
43. Rosenberg HF, Dyer KD, Domachowske JB. 2009. Respiratory viruses and eosinophils: exploring the connections. Antiviral Res. 83:1-9. http://dx.doi.org/10.1016/j.antiviral.2009.04.005.
44. Castilow EM, Legge KL, Varga SM. 2008. Cutting edge: eosinophils do not contribute to respiratory syncytial virus vaccine-enhanced disease. J. Immunol. 181:6692-6696. http://dx.doi.org/10.4049/jimmunol.181.10.6692.
45. Percopo CM, Qiu Z, Phipps S, Foster PS, Domachowske JB, Rosenberg HF. 2009. Pulmonary eosinophils and their role in immunopathologic responses to formalin-inactivated pneumonia virus of mice. J. Immunol. 183:604-612. http://dx.doi.org/10.4049/jimmunol.0802270.
46. Horner AA, Raz E. 2003. Do microbes influence the pathogenesis of allergic diseases? Building the case for Toll-like receptor ligands. Curr. Opin. Immunol. 15:614-619. http://dx.doi.org/10.1016/j.coi.2003.09.021.
47. Vercelli D. 2006. Mechanisms of the hygiene hypothesis-molecular and otherwise. Curr. Opin. Immunol. 18:733-737. http://dx.doi.org/10.1016/j.coi.2006.09.002.
48. Khanolkar A, Hartwig SM, Haag BA, Meyerholz DK, Harty JT, Varga SM. 2009. Toll-like receptor 4 deficiency increases disease and mortality after mouse hepatitis virus type 1 infection of susceptible C3H mice. J. Virol. 83:8946-8956. http://dx.doi.org/10.1128/JVI.01857-08.
49. Sheahan T, Morrison TE, Funkhouser W, Uematsu S, Akira S, Baric RS, Heise MT. 2008. MyD88 is required for protection from lethal infection with a mouse-adapted SARS-CoV. PLoS Pathog. 4:e1000240. http://dx.doi.org/10.1371/journal.ppat.1000240.
50. Cervantes-Barragan L, Zust R, Weber F, Spiegel M, Lang KS, Akira S, Thiel V, Ludewig B. 2007. Control of coronavirus infection through plasmacytoid dendritic-cell-derived type I interferon. Blood 109:1131-1137. http://dx.doi.org/10.1182/blood-2006-05-023770.
51. Zhao J, Wohlford-Lenane C, Zhao J, Fleming E, Lane TE, McCray PB, Jr, Perlman S. 2012. Intranasal treatment with poly(I·C) protects aged mice from lethal respiratory virus infections. J. Virol. 86:11416-11424. http://dx.doi.org/10.1128/JVI.01410-12.
52. Erlandsson L, Blumenthal R, Eloranta ML, Engel H, Alm G, Weiss S, Leanderson T. 1998. Interferon-beta is required for interferon-alpha production in mouse fibroblasts. Curr. Biol. 8:223-226. http://dx.doi.org/10.1016/S0960-9822(98)70086-7.
53. Biron CA. 1998. Role of early cytokines, including alpha and beta interferons (IFN-alpha/beta), in innate and adaptive immune responses to viral infections. Semin. Immunol. 10:383-390. http://dx.doi.org/10.1006/smim.1998.0138.
54. Kanzler H, Barrat FJ, Hessel EM, Coffman RL. 2007. Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists. Nat. Med. 13:552-559. http://dx.doi.org/10.1038/nm1589.
55. Horscroft NJ, Pryde DC, Bright H. 2012. Antiviral applications of Tolllike receptor agonists. J. Antimicrob. Chemother. 67:789-801. http://dx.doi.org/10.1093/jac/dkr588.
56. Keyaerts E, Vijgen L, Maes P, Duson G, Neyts J, Van Ranst M. 2006. Viral load quantitation of SARS-coronavirus RNA using a one-step realtime RT-PCR. Int. J. Infect. Dis. 10:32-37. http://dx.doi.org/10.1016/j.ijid.2005.02.003.